Short Interest in Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Expands By 44.9%

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 368 shares, a growth of 44.9% from the December 15th total of 254 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 3,296 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 3,296 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are short sold.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several hedge funds have recently made changes to their positions in AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new position in Ascentage Pharma Group International in the 3rd quarter worth $96,000. ABC Arbitrage SA acquired a new position in shares of Ascentage Pharma Group International in the third quarter valued at about $204,000. Chevy Chase Trust Holdings LLC purchased a new position in shares of Ascentage Pharma Group International in the second quarter worth about $227,000. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the third quarter worth about $383,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International during the second quarter worth about $391,000.

Analysts Set New Price Targets

Several analysts have commented on the stock. BTIG Research assumed coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They set a “buy” rating and a $50.00 price target for the company. Oppenheimer assumed coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They set an “outperform” rating and a $45.00 target price for the company. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Piper Sandler began coverage on Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price target on the stock. Finally, Rodman & Renshaw assumed coverage on Ascentage Pharma Group International in a report on Tuesday. They set a “buy” rating and a $48.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $48.40.

Ascentage Pharma Group International Trading Down 0.9%

NASDAQ:AAPG opened at $27.05 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53. Ascentage Pharma Group International has a twelve month low of $16.50 and a twelve month high of $48.45. The company’s 50 day moving average is $29.68 and its two-hundred day moving average is $35.81.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.